Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

719
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
719
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

593
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
593
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

1.8K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
1.8K
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

1.1K
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.1K
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

1.3K
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
1.3K
Other Pulmonary Disorders01:17

Other Pulmonary Disorders

1.8K
Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genome-wide association study reveals a novel tuberculosis susceptibility locus in multiple East Asian and European populations.

Genome medicine·2026
Same author

Loss of 7-Dehydrocholesterol Reductase mediated cholesterol biosynthesis activates IRF3 and inhibits control of <i>Mycobacterium marinum</i> infection.

bioRxiv : the preprint server for biology·2026
Same author

A Cationic Supramolecule With Potent Antifungal Activity, Single-Species Selectivity, and Strong Synergy With Echinocandins.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

A bioluminescence-based chemical screen identifies a bactericidal naphthalen-1-ylmethanamine scaffold targeting MmpL3 in Mycobacterium abscessus.

Cell reports·2026
Same author

Particulate Bone Grafts vs Split Bone Cortical Plates: Resorbable and Nonresorbable Membranes in Vertical Augmentation.

The Journal of oral implantology·2026
Same author

Knockout Serum Replacement Accompanied With Basic Fibroblast Growth Factor in Culture Medium Promotes Growth of Human Breast Milk-Derived Cells.

The journal of obstetrics and gynaecology research·2026
Same journal

The Biology of Malaria Parasite Liver Infection.

Cold Spring Harbor perspectives in medicine·2026
Same journal

The Interaction between Diabetes Mellitus and Tuberculosis: Epidemiology, Screening, and Clinical Management.

Cold Spring Harbor perspectives in medicine·2026
Same journal

New Malaria Prevention Modalities: Long-Acting Interventions Beyond Vaccines.

Cold Spring Harbor perspectives in medicine·2026
Same journal

From Parasite to Pill: Harnessing Biology for Breakthroughs in Antimalarial Drug Discovery.

Cold Spring Harbor perspectives in medicine·2026
Same journal

Malaria Parasite Genomics: Decentralization, Diversification, and Development Goals.

Cold Spring Harbor perspectives in medicine·2026
Same journal

Tuberculosis Infection: Diagnosis and Management.

Cold Spring Harbor perspectives in medicine·2026
See all related articles

Related Experiment Video

Updated: Mar 11, 2026

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.3K

Host-Directed Therapies for Tuberculosis.

Stefan H Oehlers1,2, Sakshi Agarwal3, Amit Singhal3,2,4

  • 1A*STAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), Singapore 308232, Republic of Singapore stefan_oehlers@a-star.edu.sg.

Cold Spring Harbor Perspectives in Medicine
|March 9, 2026
PubMed
Summary
This summary is machine-generated.

Host-directed therapies (HDTs) repurpose existing drugs to combat tuberculosis (TB). This review examines evidence for HDTs, offering a faster, cost-effective approach to reducing TB

More Related Videos

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

9.2K
A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

8.4K

Related Experiment Videos

Last Updated: Mar 11, 2026

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.3K
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

9.2K
A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

8.4K

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Immunology

Background:

  • Tuberculosis (TB) remains a significant global health challenge.
  • Traditional drug discovery for TB is lengthy and expensive.
  • Host-directed therapies (HDTs) offer an alternative strategy by enhancing the host's immune response.

Purpose of the Study:

  • To review the evidence supporting drug repurposing for TB HDTs.
  • To identify promising drug candidates for future clinical trials.
  • To explore the potential of HDTs in reducing TB burden and post-treatment lung disease.

Main Methods:

  • Comprehensive review of preclinical data.
  • Analysis of retrospective clinical studies.
  • Evaluation of randomized controlled trial (RCT) evidence for repurposed drugs.

Main Results:

  • Several repurposed drugs show promise as TB HDTs.
  • Evidence spans from laboratory studies to clinical trials.
  • Some therapeutic agents require further development.

Conclusions:

  • Drug repurposing is a viable and efficient strategy for developing TB HDTs.
  • HDTs are expected to play a crucial role in TB control.
  • Further research and clinical trials are needed to advance promising candidates.